Table 5.
Pharmacokinetic parameters of rituximab
| Arm | Dose (mg/day) | AUC (µg. h/mL) | Cmax † (µg/mL) | T1/2 (h) | Clearance ‡ (litter/h) | MRT (h) | Vd (litter) | |
|---|---|---|---|---|---|---|---|---|
| Arm C | Mean | 593.9 | 372 498.9 | 262.5 | 232.3 | 0.0259 | 335.1 | 4.49 |
| (n = 14) | SD | 51.1 | 111 660.4 | 73.2 | 113.8 | 0.0301 | 164.2 | 0.66 |
| Arm S | Mean | 596.4 | 418 901.3 | 433.5 | 356.9 | 0.0128 | 514.9 | 5.57 |
| (n = 13) | SD | 82.6 | 107 002.6 | 134.9 | 163.4 | 0.0077 | 235.9 | 1.95 |
†
Actual measured value.
‡
Calculated under the one‐compartment model. Time points for serum collection were as follows; Arm C: before, and 10 min and 2 days after each rituximab infusion, and 1 week, 1, 4 and 6 months after the sixth rituximab infusion. Arm S: before, 10 min after each rituximab infusion and 2 days, 1 and 2 weeks, and 1 and 4 months after the sixth rituximab infusion. AUC, area under the curve; Cmax, maximum concentration; T1/2, elimination half‐life; MRT, mean residence time; Vd, volume of distribution.